{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:18:31Z","timestamp":1777515511137,"version":"3.51.4"},"reference-count":50,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:p>This was a prospective study comparing two groups: personalized and non-personalized treatment with P2Y12 receptor blockers during a 12-month follow-up. We aimed to investigate whether personalized antiplatelet treatment in patients with high on-treatment platelet reactivity (HTPR) improves clinical outcome. Platelet reactivity was assessed by adenosine diphosphate induced aggregation using a multiple electrode aggregometry (MEA) in 798 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). Patients with HTPR received up to four repeated loading doses of clopidogrel or prasugrel in the personalized treatment group (n=403), whereas no change in the treatment strategy was undertaken in patients with HTPR in the non-personalized treatment group (n=395). There were fewer major adverse cardiac events (MACE) in the personalized treatment group than in the non-personalized treatment group (7.4% compared with 15.3% respectively; P&amp;lt;0.001). The multivariate Cox regression analysis showed that the relative risk to develop MACE was 51% lower in the personalized treatment group as compared with the non-personalized treatment group [hazard ratio (HR)=0.49; 95% confidence interval (CI): 0.31\u20130.77; P&amp;lt;0.001]. Similarly, there was a clear net benefit of the personalized antiplatelet treatment over the non-personalized treatment (ischemic and bleedings events: 8.2% versus 18.7% respectively; HR=0.46; 95%CI: 0.29\u20130.70; P&amp;lt;0.001). Further analysis indicated that patients with aggregation values within the therapeutic window (21\u201349\u00a0units) experienced the lowest event rates (stent thrombosis and major bleeding: 2.5%) as compared with poor responders (\u226550 units: 5.4%) or ultra-responders (0\u201320 units: 5.2%). In conclusion, personalized antiplatelet treatment might improve patients\u2019 outcome without increasing bleeding complications compared with the non-personalized treatment during a 12-month follow-up.<\/jats:p>","DOI":"10.1042\/cs20140310","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T08:50:10Z","timestamp":1408351810000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention"],"prefix":"10.1042","volume":"128","author":[{"given":"Jolanta\u00a0M.","family":"Siller-Matula","sequence":"first","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Gruber","sequence":"additional","affiliation":[{"name":"5th Medical Department of Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Francesconi","sequence":"additional","affiliation":[{"name":"5th Medical Department of Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Dechant","sequence":"additional","affiliation":[{"name":"5th Medical Department of Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Delle-Karth","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Grohs","sequence":"additional","affiliation":[{"name":"Clinical Institute for Laboratory Medicine, Kaiser Franz Josef Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Podczeck-Schweighofer","sequence":"additional","affiliation":[{"name":"5th Medical Department of Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Christ","sequence":"additional","affiliation":[{"name":"5th Medical Department of Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"key":"2021113010342808000_B1","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jcin.2013.06.011","article-title":"Response variability to P2Y12 receptor inhibitors: expectations and reality","volume":"6","author":"Siller-Matula","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"2021113010342808000_B3","article-title":"How to improve the concept of individualized antiplatelet therapy with P2Y12 receptor inhibitors\u2013is an algorithm the answer?","author":"Siller-Matula","year":"2014","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":"A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75\u00a0mg of clopidogrel for 30 days","volume":"28","author":"von Beckerath","year":"2007","journal-title":"Eur. Heart J."},{"key":"2021113010342808000_B5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2007.05.049","article-title":"Impact of platelet reactivity on cardiovascular outcomes in patients with type\u00a02 diabetes mellitus and coronary artery disease","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1160\/TH07-09-0562","article-title":"Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study","volume":"99","author":"Angiolillo","year":"2008","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"2021113010342808000_B8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/fca.10.89","article-title":"Ticagrelor: from discovery to clinical trial phase III","volume":"6","author":"Siller-Matula","year":"2010","journal-title":"Future Cardiol."},{"key":"2021113010342808000_B10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1472-8206.2011.00986.x","article-title":"Pharmacokinetic basis of the antiplatelet action of prasugrel","volume":"26","author":"Schror","year":"2012","journal-title":"Fundam. Clin. Pharmacol."},{"key":"2021113010342808000_B11","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up","author":"Kozinski","year":"2014","journal-title":"Cardiol. J."},{"key":"2021113010342808000_B12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1185\/03007995.2014.880050","article-title":"Cangrelor: an emerging therapeutic option for patients with coronary artery disease","volume":"30","author":"Kubica","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"2021113010342808000_B13","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study","volume":"167","author":"Siller-Matula","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021113010342808000_B14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1160\/TH13-03-0250","article-title":"Why have studies of tailored anti-platelet therapy failed so far?","volume":"110","author":"Siller-Matula","year":"2013","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3109\/09537104.2011.582900","article-title":"Diurnal variation in platelet inhibition by clopidogrel","volume":"22","author":"Kozinski","year":"2011","journal-title":"Platelets"},{"key":"2021113010342808000_B16","first-page":"535","article-title":"Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome","volume":"16","author":"Kasprzak","year":"2009","journal-title":"Cardiol. J."},{"key":"2021113010342808000_B17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1537-2995.2009.02554.x","article-title":"The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo","volume":"50","author":"Mayr","year":"2010","journal-title":"Transfusion"},{"key":"2021113010342808000_B18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1042\/CS20120194","article-title":"Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial","volume":"123","author":"Spiel","year":"2012","journal-title":"Clin. Sci."},{"key":"2021113010342808000_B19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ijcard.2012.01.016","article-title":"Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin","volume":"167","author":"Siller-Matula","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021113010342808000_B20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1538-7836.2009.03699.x","article-title":"Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"2021113010342808000_B21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J. Am. Coll Cardiol."},{"key":"2021113010342808000_B22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study","volume":"10","author":"Siller-Matula","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"2021113010342808000_B23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH06-05-0242","article-title":"Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood","volume":"96","author":"Toth","year":"2006","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B24","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2021113010342808000_B25","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/hrt.2008.151233","article-title":"The universal definition of myocardial infarction: a consensus document: ischaemic heart disease","volume":"94","author":"Alpert","year":"2008","journal-title":"Heart"},{"key":"2021113010342808000_B26","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur. Heart J."},{"key":"2021113010342808000_B27","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021113010342808000_B28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"2021113010342808000_B29","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study","volume":"59","author":"Trenk","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1160\/TH13-03-0250","article-title":"Why have studies of tailored anti-platelet therapy failed so far?","volume":"110","author":"Siller-Matula","year":"2013","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"2021113010342808000_B32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1160\/TH09-11-0803","article-title":"Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel","volume":"104","author":"Bal Dit Sollier","year":"2010","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jacc.2013.12.023","article-title":"Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel","volume":"63","author":"Aradi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/jth.12073","article-title":"Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays","volume":"11","author":"Consuegra-Sanchez","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"2021113010342808000_B35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B36","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur. Heart J."},{"key":"2021113010342808000_B37","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"2021113010342808000_B38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ahj.2011.07.026","article-title":"Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150\u00a0mg) clopidogrel","volume":"162","author":"Alexopoulos","year":"2011","journal-title":"Am. Heart J."},{"key":"2021113010342808000_B39","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","article-title":"Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and high on-treatment platelet reactivity","volume":"9","author":"Alexopoulos","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"2021113010342808000_B40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"2021113010342808000_B41","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B42","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1016\/j.thromres.2013.05.029","article-title":"Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy","volume":"132","author":"Christ","year":"2013","journal-title":"Thromb. Res."},{"key":"2021113010342808000_B43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1160\/TH13-03-0203","article-title":"Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay","volume":"110","author":"Abtan","year":"2013","journal-title":"Thromb. Haemost."},{"key":"2021113010342808000_B44","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"for the A-DESI (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","journal-title":"Lancet"},{"key":"2021113010342808000_B45","first-page":"Suppl. B, XII","article-title":"A large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Results from the ADAPT-DES study","volume":"58","author":"Stone","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B46","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","article-title":"Platelet function monitoring in patients with coronary artery disease","volume":"50","author":"Gurbel","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1538-7836.2009.03709.x","article-title":"Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement","volume":"8","author":"Sibbing","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"2021113010342808000_B48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window","volume":"56","author":"Sibbing","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B49","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome","volume":"57","author":"Campo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010342808000_B50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jth.12445","article-title":"Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors","volume":"12","author":"Siller-Matula","year":"2014","journal-title":"J. Thromb. Haemost."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/128\/2\/121\/446185\/cs1280121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/128\/2\/121\/446185\/cs1280121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:26:38Z","timestamp":1638271598000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/128\/2\/121\/70863\/The-net-clinical-benefit-of-personalized"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20140310","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]}}}